Literature DB >> 9018068

Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors.

A F Shering1, D Bain, K Stewart, A L Epstein, M G Castro, G W Wilkinson, P R Lowenstein.   

Abstract

Expression from a short human cytomegalovirus (HCMV) major immediate early (IE) promoter-enhancer was tested in three different virus vectors: recombinant adenovirus (Ad), recombinant herpes simplex virus type 1 (HSV-1) and HSV-1-derived amplicon vectors. The HCMV major IE promoter-enhancer within a replication-deficient recombinant Ad vector was shown to produce cell-specific expression in rat nervous system cell cultures. Recombinant Ad entered all cell types examined but the HCMV major IE promoter was silent in primary cultures of neocortical neurons and Schwann cells, although it drove transgene expression in astrocytes and fibroblasts. Moreover, in neurons and Schwann cells, expression from the HCMV major IE promoter-enhancer in the replication-deficient Ad vector was activated by superinfection with HSV-1, replication-competent Ad and HCMV. The HCMV major IE promoter-enhancer was active in neurons when inserted into HSV-1 recombinant vectors. Further experiments with HSV-1-derived amplicons strongly suggested that an IE protein was responsible for the activation of HCMV major IE-induced expression in neurons. This demonstrates that the activity of the HCMV major IE promoter-enhancer element can depend on the expression of other genes encoded in the virus vector backbone within which it is inserted, and that it can function in a neuronal cell type-specific manner when inserted into a replication-deficient Ad vector.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9018068     DOI: 10.1099/0022-1317-78-2-445

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  21 in total

1.  Kinetics of recombinant adeno-associated virus-mediated gene transfer.

Authors:  A K Malik; P E Monahan; D L Allen; B G Chen; R J Samulski; K Kurachi
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 2.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

3.  Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction.

Authors:  M Puntel; J F Curtin; J M Zirger; A K M Muhammad; W Xiong; C Liu; J Hu; K M Kroeger; P Czer; S Sciascia; S Mondkar; P R Lowenstein; M G Castro
Journal:  Hum Gene Ther       Date:  2006-05       Impact factor: 5.695

4.  Rapid upregulation of interferon-regulated and chemokine mRNAs upon injection of 108 international units, but not lower doses, of adenoviral vectors into the brain.

Authors:  Jeffrey M Zirger; Carlos Barcia; Chunyan Liu; Mariana Puntel; Ngan Mitchell; Iain Campbell; Maria Castro; Pedro R Lowenstein
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells.

Authors:  Carlos Barcia; Christian Gerdes; Wei-Dong Xiong; Clare E Thomas; Chunyan Liu; Kurt M Kroeger; Maria G Castro; Pedro R Lowenstein
Journal:  Neuron Glia Biol       Date:  2006-11

6.  Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus.

Authors:  Matteo Iannacone; Giovanni Sitia; Iñigo Narvaiza; Zaverio M Ruggeri; Luca G Guidotti
Journal:  Clin Vaccine Immunol       Date:  2007-09-19

7.  Adenoviruses encoding HPRT correct biochemical abnormalities of HPRT-deficient cells and allow their survival in negative selection medium.

Authors:  T D Southgate; D Bain; L D Fairbanks; A E Morelli; A T Larregina; H A Simmonds; M G Castro; P R Löwenstein
Journal:  Metab Brain Dis       Date:  1999-12       Impact factor: 3.584

8.  Neuronal expression of the transcription factor Gli1 using the Talpha1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease.

Authors:  D Suwelack; A Hurtado-Lorenzo; E Millan; V Gonzalez-Nicolini; K Wawrowsky; P R Lowenstein; M G Castro
Journal:  Gene Ther       Date:  2004-12       Impact factor: 5.250

9.  Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.

Authors:  Sumia Ali; Gwendalyn D King; James F Curtin; Marianela Candolfi; Weidong Xiong; Chunyan Liu; Mariana Puntel; Queng Cheng; Jesus Prieto; Antoni Ribas; Jerzy Kupiec-Weglinski; Nico van Rooijen; Hans Lassmann; Pedro R Lowenstein; Maria G Castro
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

10.  Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration.

Authors:  A Hurtado-Lorenzo; E Millan; V Gonzalez-Nicolini; D Suwelack; M G Castro; P R Lowenstein
Journal:  Mol Ther       Date:  2004-09       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.